Drug formulation as solid dispersion (SD) represents a good method for the enhancement in solubility of poorly water soluble drugs, as well as for the reduction of ulcergenicity of non-sterodial anti-inflammatory drugs (NSAID). The poorly water soluble Meloxicam (MLX) was used as model drug to prepare solid dispersion. Solid dispersion of MLX was prepared by melting method, using Poloxamer 188 as hydrophilic carrier. A 32 factorial design was used to study the influence of individual and combined effects of 2 factors (drug:polymer ratio and cooling temperature) on the responses. Using the polynomial equation describing the effect estimates on the dependent variables and the surface response methodology, an optimal formulation was developed. A drug:polymer ratio of 1:4.69 and a cooling temperature of 5˚C were found to be the optimum values for the independent variables. The optimized solid dispersion was further characterized by differential scanning calorimetry (DSC), Fourier transform infrared spectroscopy (FT-IR) and X-ray powder diffraction (XRD) analysis, whereas the dissolution behavior was studied in 900 ml of 0.25% w/v sodium lauryl sulphate solution by means of USP Apparatus 2 (50 rpm). The results confirmed obtaining of a solid dispersion of low crystallinity with a complete in vitro release of the active substance within 60 minutes. 

Objectives: This study includes preparation, evaluation and in-vitro release profiles of erythropioten (EPO) microcapsules using poly lactic-co-glycolic acid (PLGA) polymer as coating material. Sustained release dosage form was grown up especially in the treatments of chronic disease to improve the drug efficacy, reduce side effects and improve patient compliance. EPO is a protein produced by the kidney to respond to a different type of anemia. Methods: Microcapsules of EPO with prolonged-release profile were prepared by double emulsion method (wow) using probe sonicator to get a homogenous double emulsion. PLGA was used as wall material. Results: Eleven formulas of EPO-PLGA microcapsules were prepared to study the effect of different variables on the entrapment efficiency (EE) and %yield including the addition of plasticizer, NaCl, PLGA concentration and mixing type’s effect. The selected formula containing 95000 IU of EPO gave (89%) EE and (85%) %yield with particle size 293.5 nm, zeta potential -41.33 with prolonged-release profile (99.7% within 6 months). Such formula is suggested to be incorporated in a suitable implantable dosage form to treat anemia associated with renal disorder. Conclusion: EPO was successfully microcapsulated using PLGA polymer as a coat material by double emulsion method with good EE, %yield, particle size, and prolonged release profile continued up to 6 months.